Nasdaq4d
FDA Accepts BLA Reubmission For Regeneron's Odronextamab In Follicular Lymphoma
Odronextamab is approved as Ordspono in the European Union for the treatment of R/R FL or diffuse large B-cell lymphoma (DLBCL). The views and opinions expressed herein are the views and opinions ...
Nasdaq4d
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
About the Odronextamab Clinical Development ProgramOdronextamab is a CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell ...